TenNor Therapeutics (Suzhou) Limited

Performance in the 2026 Benchmark

Performs well. TenNor has the largest pipeline among its peers, with five projects in development. Although all projects target ‘high’ or ‘critical’ priority pathogens, none are categorised as innovative according to WHO’s criteria. It has a moderate performance in access and stewardship planning. Although plans are in place, there is room for improvement as they remain limited in depth and breadth. 

Opportunities for TenNor

Expand access and stewardship plans for TNP-2092 beyond China. TenNor’s pipeline, which focuses on bacterial biofilms, mostly targets methicillin-resistant S.aureus (MRSA), with one discovery-stage project focused on carbapenem-resistant A. baumannii. For TNP-2092, an antibacterial medicine targeting MRSA included in three late-stage projects, the company reports only limited access plans for China and provides no information on stewardship. TenNor can strengthen its China-focused plans by integrating stewardship provisions and, as operational capacity grows, expand its activities beyond China while broadening its access and stewardship planning. It can ultilise the  Stewardship & Access Plan (SAP) Development Guide and work with partners to strengthen its approach, focusing on regions with high levels of resistance and significant clinical need, particularly in settings with limited or no treatment options. 

Sales & Operations

• Therapeutic areas: Anti-infectives 

• Financial stage: Private (Series E financing of over RMB 300mn achieved in October 2024, filed for Hong Kong Stock Exchange listing in July 2025) 

• Products on the market: None 

• Commercial partners: TenNor partners with Grand Life Sciences for rifasutenizol commercialisation in China. 

• Funding partners: TenNor has secured funding from a diverse group of investors including the AMR Action Fund, Northern Light Venture Capital, WuXi AppTec, Zhongshan Venture Capital and other existing investors. 

Sample of pipeline assessed by the Benchmark

Pipeline for diseases in scope

Research & Development

Pipeline of antibacterial medicines targeting critical and high-priority pathogens, but no innovative candidates. TenNor Therapeutics has 5 projects in its pipeline targeting pathogens in scope. These 5 projects are based on 2 distinct antibacterial medicines: the first, TNP-2092, is currently in clinical development for 3 different routes of administration (intravenous, intra-articular and topical) for 3 different indications focusing on bacterial biofilms. The other medicine is a bifunctional molecule indicated for carbapenem-resistant Acinetobacter baumannii (CRAB) infections. (See figure above for TenNor’s full pipeline breakdown including drug development phases and disease targets). Each project targets 1 priority pathogen, including CRAB classified as ‘critical’, and methicillin-resistant Staphylococcus aureus (MRSA) classified as ‘high’ priority on WHO’s bacterial priority pathogen list.  TNP-2092 was assessed but did not meet any of WHO’s 4 innovation criteria. The company has an active in-house discovery programme focused on CRAB.     

Limited access and stewardship planning for 3 projects. TenNor has 3 projects in late-stage development and reports limited access planning for these projects. Although the company reports access planning related to registration, manufacturing and commercialisation in China, further access plans or stewardship plans for other countries in scope have not been disclosed.